Structural and biophysical analysis of important biomedical enzymes and nano-architectures by Chattopadhyay, Arundhati
Structural and Biophysical Analysis of Important 
Biomedical Enzymes and 
Nano-architectures 
 
  
  
  
  
  
  
 
  
Inauguraldissertation 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenchaftlichen Fakultät 
der Universität Basel 
 
 
 
 
 
 
Von 
 
 
Arundhati Chattopadhyay 
 
Aus 
 
Indien 
 
 
Basel, 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genehmigt von der Philosophisch-Naturwissenschaftichen Fakultät 
 
Auf Antrag von  
 
Professor. Dr. Ueli Aebi (University of Basel, Switzerland)  
 
Und  
 
Associate Professor. Dr. Peter Burkhard (University of Connecticut, USA)  
 
Und  
 
Professor. Dr. Tilman Schirmer (University of Basel, Switzerland)  
 
 
 
  
Basel, den 14 Oktober 2008 
 
  
  
                                                                                Prof. Dr. Eberhard Parlow 
                                                                                                          (Dekan) 
 1
 CONTENTS 
 
CHAPTER 1 ...............................................................................................................................................5 
STRUCTURE, MECHANISM, AND CONFORMATIONAL DYNAMICS OF O-ACETYL 
SERINE SULFHYDRYLASE FROM SALMONELLA TYPHIMURIUM: COMPARISON OF A 
AND B ISOZYMES†.................................................................................................................................5 
CHAPTER 2 .............................................................................................................................................22 
PURIFICATION AND CHARACTERIZATION OF HUMAN DOPA-DECARBOXYLASE.....22 
LIST OF ABBREVIATIONS.................................................................................................................24 
2.1. ABSTRACT...............................................................................................................................26 
2.2. INTRODUCTION........................................................................................................................27 
2.2.1. The Enzyme DOPA Decarboxylase...................................................................................27 
2.2.2. Physiological Importance and Regulation of DDC..........................................................28 
2.2.3. Clinical Relevance of DDC...............................................................................................28 
2.2.3.1. Parkinson’s Disease and it’s Treatment.................................................................................28 
2.2.3.2. Schizophrenia .........................................................................................................................29 
2.2.3.3. Cancer.....................................................................................................................................30 
2.2.4. DOPA Decarboxylase - A member of PLP Dependent Enzyme.......................................30 
2.2.4.1. What is PLP?..........................................................................................................................30 
2.2.4.2. PLP is One of Nature’s Most Versatile Catalysts .................................................................30 
2.2.4.3. Ketoenamine and Enolenamine Tautomeric Equilibrium.....................................................32 
2.2.5. Structure of Pig-kidney DDC – A Clue to the Structure of Human DDC?......................33 
2.2.5.1. Structure of pig-kidney DDC.................................................................................................33 
2.2.5.2. Active Site ..............................................................................................................................34 
2.2.5.3. Inhibitor Binding Mechanism................................................................................................35 
2.2.5.4. Sequence Homology of Pig-kidney DDC and Human DDC ................................................36 
2.2.5.5. Structure Based Drug Design.................................................................................................36 
2.3. SCOPE OF THE WORK..............................................................................................................37 
2.4. MATERIALS AND METHODS ....................................................................................................38 
2.4.1. Subcloning into an E.coli expression vector.....................................................................38 
2.4.2. Overcoming the problem of inclusion body formation of recombinant DDC .................38 
2.4.2.1. pET-DDC-His transformed in BL21(DE3) codon plus ........................................................38 
2.4.2.2. pET32a (His and thioredoxin fusion) transformed in Rosetta cells......................................38 
2.4.2.3. pGEXT-DDCHis (His and GST- fusion) ..............................................................................39 
2.4.2.4. Addition of varied amount of IPTG – A controlled expression system................................39 
2.4.2.5. Addition of PLP in the growth medium ................................................................................39 
2.4.2.6. Addition of Sorbitol and Betaine complex ............................................................................40 
2.4.2.7. Addition of Ethanol................................................................................................................39 
2.4.3. Preparation of the Crude Extract of Recombinant DDC .................................................40 
2.4.4. Expression and Purification of Recombinant DDC .........................................................40 
2.4.5. Determination of Protein Concentration..........................................................................41 
2.4.6. SDS-PAGE, Blue Native PAGE and Western Blot ...........................................................41 
2.4.7. Mass Spectrometry ............................................................................................................42 
2.4.8. Multi-Angle Light Scattering (MALS)...............................................................................42 
2.4.9. Enzymatic Assay ................................................................................................................43 
2.4.10. Crystallization ..............................................................................................................44 
2.5. RESULTS..................................................................................................................................45 
2.5.1. Overcoming the problem of inclusion body formation of recombinant DDC .................45 
2.5.1.1. pET-DDC-His Transformed in BL21(DE3)Codon-Plus.......................................................45 
2.5.1.2. Addition of Varied Amount of IPTG – Controlled Expression System ...............................45 
2.5.1.3. Addition of PLP in the Growth Medium ...............................................................................46 
2.5.1.4. Addition of Sorbitol and Betaine Complex ...........................................................................47 
2.5.1.5. Addition of Ethanol................................................................................................................48 
2.5.1.6. Changing Temperature...........................................................................................................49 
2.5.1.7. pGEXT-DDCHis (His and GST fusion) and pET32a (His and Thioredoxin Fusions) 
Transformed in Rosetta Cells ......................................................................................................................50 
 2
2.5.1.8. Cotransformation with pGroELS (GroEL and GroES Containing Vector) Plasmid............51 
2.5.1.9. Confirmation and Characterization of DDC Using Western Blot ........................................52 
2.5.2. Expression and Purification of Recombinant DDC after Coexpression with proGroELS
 ……………………………………………………………………………………………………...53 
2.5.2.1. Purification: Hi trap Ni column and Gel Filtration Column .................................................53 
2.5.3. Molecular Weight Determination- Size Exclusion Chromatography and Multi-Angle 
Light Scattering................................................................................................................................55 
2.5.4. Effect of Temperature........................................................................................................57 
2.5.5. Effect of NDSB in Dimerization ........................................................................................58 
2.5.6. Mass Spectrometry ............................................................................................................59 
2.5.7. Determination of Protein Concentration..........................................................................62 
2.5.8. UV-Visible Spectral characteristics..................................................................................62 
2.5.9. Enzymatic Assay ................................................................................................................64 
2.5.10. Crystallization ..............................................................................................................64 
2.6. DISCUSSIONS...........................................................................................................................65 
2.7. APPENDIX................................................................................................................................69 
2.7.1. pET-DDC-His Vector Map................................................................................................69 
2.7.2. pET-32a-DDC Plasmid Map.............................................................................................70 
2.7.3. pGEXT-DDC-His Vector Map (GST Coding Gene Tagged) ...........................................71 
2.8. REFERENCES ...........................................................................................................................72 
CHAPTER 3 .............................................................................................................................................75 
DE-NOVO DESIGNED NANOPARTICLES - AN EFFICIENT PHARMACOLOGICAL TOOL
....................................................................................................................................................................75 
LIST OF ABBREVIATIONS.................................................................................................................76 
3.1. ABSTRACT...............................................................................................................................78 
3.2. INTRODUCTION........................................................................................................................79 
3.2.1. Nanoparticles.....................................................................................................................79 
3.2.2. Peptide Nanoparticles .......................................................................................................79 
3.2.3. Peptide Nanoparticles and Drug Delivery .......................................................................79 
3.2.4. Peptide Nanoparticles and Vaccine Design .....................................................................81 
3.2.4.1. Vaccine for HIV.....................................................................................................................81 
3.2.4.2. What are gp41, gp120 and gp 160? .......................................................................................81 
3.2.4.3. Vaccination Strategy:.............................................................................................................82 
3.2.4.4. HIV-1 Vaccine Design...........................................................................................................85 
3.2.5. Nanoparticles and Biosensing...........................................................................................85 
3.2.5.1. What is Biosensing?...............................................................................................................85 
3.2.5.2. Peptide Nanoparticles in Biosensing .....................................................................................85 
3.2.5.2.1. Cancer Therapy.................................................................................................................86 
3.2.5.3. Gold Attached Peptide-Nanoparticle and Biosensing ...........................................................86 
3.2.5.3.1. Objectives .........................................................................................................................87 
3.2.5.4. Development of Peptide Nanoparticle Based Serodiagnosis Tools for M.tuberculosis .......87 
3.2.5.4.1. Clinical manifestation of Tuberculosis ............................................................................88 
3.2.5.4.2. Diagnosis of Tuberculosis ................................................................................................88 
3.2.5.4.3. Difficulties in Diagnosis...................................................................................................89 
3.2.5.4.4. Serological Diagnostic System.........................................................................................90 
3.2.5.4.5. Peptide Nanoparticle in Serodiagnosis of Tuberculosis ..................................................91 
3.3. OBJECTIVE OF THE CURRENT RESEARCH................................................................................92 
3.4. MATERIALS AND METHODS ....................................................................................................92 
3.4.1. Design ................................................................................................................................92 
3.4.2. Expression and Purification..............................................................................................97 
3.4.2.1. Annealing of the DNA Oligomers:........................................................................................97 
3.4.2.2. Digestion of the Expression Vector (Modified pPEP-T Vector): .........................................98 
3.4.2.3. Ligation of the four LC3 DNA Oligos with the Digested pPEP...........................................98 
3.4.2.4. Ligation of the Digested Vector and the Annealed TB1, TB2, TB3, BB3 and HIV6 
oligomers ……………………………………………………………………………………………...98 
3.4.2.5. Transformation of the Recombinant Plasmids ......................................................................99 
3.4.2.6. Expression and Purification: ..................................................................................................99 
3.4.2.7. Refolding of the Constructs: ................................................................................................100 
3.4.2.8. Gold Decoration of the Nanoparticle: Gold Seeding of the P3a_BB3 Construct:..............100 
 3
3.4.3. Dynamic Light Scattering................................................................................................100 
3.4.4. Circular Dichroism Spectroscopy: .................................................................................101 
3.4.5. Electron Microscopy .......................................................................................................101 
3.4.6. ELISA...............................................................................................................................101 
3.5. RESULTS................................................................................................................................103 
3.5.1. Expression and Purification............................................................................................103 
3.5.1.1. Annealing of the DNA Oligomers .......................................................................................103 
3.5.1.1.1. LC3 Construct.................................................................................................................103 
3.5.1.2. Transformation of the DH5α E. coli Strain with the Recombinant Expression Vector 
pPEPT: …………………………………………………………………………………………….104 
3.5.1.3. Extraction of Positive Recombinant DNA Inserts: .............................................................104 
3.5.1.3.1. LC3 Construct (core particle) .........................................................................................104 
3.5.1.3.2. P3a_BB3, P3a_HIV6, LC3_TB1, LC3_TB2, LC3_TB3 ..............................................104 
3.5.1.4. Sequencing of Positive Inserts:............................................................................................104 
3.5.1.5. Expression and Purification: ................................................................................................105 
3.5.1.5.1. LC3 (core particle)..........................................................................................................105 
3.5.1.5.2. P3a_BB3 .........................................................................................................................106 
3.5.1.5.3. P3a_HIV6 .......................................................................................................................106 
3.5.1.5.4. LC3_TB1 ........................................................................................................................107 
3.5.1.5.5. LC3_TB2 ........................................................................................................................108 
3.5.1.5.6. LC3_TB3 ........................................................................................................................109 
3.5.1.6. Dialysis and Refolding:........................................................................................................110 
3.5.1.6.1. LC3 (core particle)..........................................................................................................110 
3.5.1.6.2. P3a_BB3 .........................................................................................................................110 
3.5.1.6.3. P3a_HIV6 .......................................................................................................................111 
3.5.1.6.4. LC3_TB1 ........................................................................................................................111 
3.5.1.6.5. LC3_TB2 ........................................................................................................................111 
3.5.1.6.6. LC3_TB3 ........................................................................................................................111 
3.5.1.6.7. Coassembly of LC3_TB1, LC3_TB2 and LC3_TB3 ....................................................111 
3.5.2. Circular Dichroism .........................................................................................................112 
3.5.2.1. LC3.......................................................................................................................................112 
3.5.2.2. P3a_BB3...............................................................................................................................113 
3.5.2.3. P3a_HIV6.............................................................................................................................113 
3.5.2.3.1. Melting Curve .................................................................................................................114 
3.5.3. Dynamic Light Scattering................................................................................................115 
3.5.3.1.1. LC3 (core particle)..........................................................................................................115 
3.5.3.1.2. P3a_BB3 .........................................................................................................................116 
In Tris buffer ...................................................................................................................................117 
In HEPES Buffer.............................................................................................................................117 
3.5.3.1.3. P3a_HIV6 .......................................................................................................................118 
In Tris- buffer..................................................................................................................................118 
In HEPES buffer .............................................................................................................................118 
3.5.3.1.4. LC3_TB1 ........................................................................................................................119 
3.5.3.1.5. LC3_TB2 ........................................................................................................................120 
3.5.3.1.6. LC3_TB3 (co-assembly of LC3 core particle and LC3_TB3 in 4:1 ratio) ...................121 
3.5.3.1.7. Co-assembly of LC3, LC3_Tb1, LC3_Tb2, LC3_Tb3 in 1:1:1:1 .................................121 
3.5.3.1.8. Co-assembly of LC3_Tb1, LC3_Tb2, LC3_Tb3 in 1:1:1 .............................................122 
3.5.4. Electron Microscopy .......................................................................................................123 
3.5.4.1. LC3 (core particle) ...............................................................................................................123 
3.5.4.2. P3a_BB3...............................................................................................................................123 
3.5.4.3. P3a_HIV6.............................................................................................................................124 
3.5.4.4. Gold Seeding – P3a_BB3 Construct....................................................................................125 
3.5.4.5. LC3_TB1..............................................................................................................................126 
3.5.4.6. LC3_TB2..............................................................................................................................127 
3.5.4.7. LC3: LC3_TB3: 4:1 .............................................................................................................128 
3.5.4.8. LC3:LC3_TB1:LC3_TB2:LC3_TB3 ..................................................................................128 
3.5.4.9. LC3_TB1:LC3_TB2:LC3_TB3: 1:1:1 ................................................................................129 
3.5.5. ELISA...............................................................................................................................130 
3.6. DISCUSSIONS.........................................................................................................................131 
3.6.1. Expression and Purification: ..........................................................................................131 
3.6.2. Stability of Nanoparticles and CD data..........................................................................132 
3.6.3. Formation of Nanoparticle .............................................................................................132 
3.6.3.1. Buffer Conditions.................................................................................................................132 
 4
3.6.4. Gold Decoration Using HAuCl4 on P3a_BB3 ...............................................................133 
3.6.5. Serodiagnostic tool for TB ..............................................................................................134 
3.6.6. ELISA...............................................................................................................................135 
3.7. APPENDIX..............................................................................................................................135 
3.7.1. pPEP Vector Map............................................................................................................135 
3.8. REFERENCES .........................................................................................................................136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Structure of O-Acetyl Serine Sulfhydrylase B 
                               
 5
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
 
 
 
Structure, Mechanism, and Conformational Dynamics 
of O-Acetyl Serine Sulfhydrylase from Salmonella 
typhimurium: Comparison of A and B Isozymes† 
 
 
 
 
(My contribution in this manuscript is the part that deals with crystallization and 
determination of the structure of OASSB enzyme). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Structure, Mechanism, and Conformational Dynamics of O-Acetylserine
Sulfhydrylase from Salmonella typhimurium: Comparison of A and B Isozymes†
Arundhati Chattopadhyay,‡,§ Markus Meier,§ Sergei Ivaninskii,| and Peter Burkhard*,§
Institute of Materials Science, UniVersity of Connecticut, 97 North EagleVille Road, Storrs, Connecticut 06269-3136, and M. E.
Mu¨ller Institute for Structural Biology, Biozentrum, UniVersity of Basel, 4056 Basel, Switzerland
Francesca Speroni,‡ Barbara Campanini,* Stefano Bettati, and Andrea Mozzarelli
Department of Biochemistry and Molecular Biology, UniVersity of Parma, 43100 Parma, Italy
Wael M. Rabeh,‡ Lei Li,⊥ and Paul F. Cook*
Department of Chemistry and Biochemistry, UniVersity of Oklahoma, 620 Parrington OVal, Norman, Oklahoma 73019
ReceiVed December 19, 2006; ReVised Manuscript ReceiVed April 2, 2007
ABSTRACT: O-Acetylserine sulfhydrylase is a pyridoxal 5′-phosphate-dependent enzyme that catalyzes
the final step in the cysteine biosynthetic pathway in enteric bacteria and plants, the replacement of the
â-acetoxy group of O-acetyl-L-serine by a thiol to give L-cysteine. Two isozymes are found in Salmonella
typhimurium, with the A-isozyme expressed under aerobic and the B-isozyme expressed under anaerobic
conditions. The structure of O-acetylserine sulfhydrylase B has been solved to 2.3 Å and exhibits overall
a fold very similar to that of the A-isozyme. The main difference between the two isozymes is the more
hydrophilic active site of the B-isozyme with two ionizable residues, C280 and D281, replacing the neutral
residues S300 and P299, respectively, in the A-isozyme. D281 is above the re face of the cofactor and is
within hydrogen-bonding distance to Y286, while C280 is located about 3.4 Å from the pyridine nitrogen
(N1) of the internal Schiff base. The B-isozyme has a turnover number (V/Et) 12.5-fold higher than the
A-isozyme and an 10-fold lower Km for O-acetyl-L-serine. Studies of the first half-reaction by rapid-
scanning stopped-flow indicate a first-order conversion of the internal Schiff base to the R-aminoacrylate
intermediate at any concentration of O-acetyl-L-serine. The Kd values for formation of the external Schiff
base with cysteine and serine, obtained by spectral titration, are pH dependent and exhibit a pKa of 7.0-
7.5 (for a group that must be unprotonated for optimum binding) with values, above pH 8.0, of about 3.0
and 30.0 mM, respectively. In both cases the neutral enolimine is favored at high pH. Failure to observe
the pKa for the R-amines of cysteine and serine in the pKESB vs pH profile suggests a compensatory effect
resulting from titration of a group on the enzyme with a pKa in the vicinity of the R-amine’s pKa. The pH
dependence of the first-order rate constant for decay of the R-aminoacrylate intermediate to give pyruvate
and ammonia gives a pKa of about 9 for the active site lysine (K41), a pH unit higher than that of the
A-isozyme. The difference in pH dependence of the pKESB for cysteine and serine, the higher pKa for
K41, and the preference for the neutral species at high pH compared to the A-isozyme can be explained
by titration of C280 to give the thiolate. Subtle conformational differences between O-acetylserine
sulfhydrylase A and O-acetylserine sulfhydrylase B are detected by comparing the absorption and emission
spectra of the internal aldimine in the absence and presence of the product acetate and of the external
aldimine with L-serine. The two isozymes show a different equilibrium distribution of the enolimine and
ketoenamine tautomers, likely as a result of a more polar active site for O-acetylserine sulfhydrylase B.
The distribution of cofactor tautomers is dramatically affected by the ligation state of the enzyme. In the
presence of acetate, which occupies the R-carboxylate subsite, the equilibrium between tautomers is shifted
toward the ketoenamine tautomer, as a result of a conformational change affecting the structure of the
active site. This finding, in agreement with structural data, suggests for the O-acetylserine sulfhydrylase
B-isozyme a higher degree of conformational flexibility linked to catalysis.
O-Acetylserine sulfhydrylase (OASS)1 catalyzes the final
reaction of the cysteine biosynthetic pathway in bacteria and
plants, the conversion of O-acetyl-L-serine (OAS) and
bisulfide to L-cysteine and acetate (1). In enteric bacteria
there are two isozymes of OASS, A and B. The B-isozyme
of O-acetylserine sulfhydrylase (OASS-B) is expressed in
† This work was supported by the Grayce B. Kerr endowment to
the University of Oklahoma to support the research of P.F.C., the Swiss
National Science Foundation and the M. E. Mueller Foundation (to
P.B.), and grants from the Italian Ministry of University and Research
(COFIN2005 to A.M.) and the International Exchange Program 2005
(to A.M. and P.F.C.). The Istituto Nazionale di Biostrutture e Biosistemi
is gratefully acknowledged.
* Corresponding authors. P.F.C.: tel, 405-325-4581; fax, 405-325-
7182; e-mail, pcook@ou.edu. P.B.: tel, 860-486-3830; fax, 860-486-
4745; e-mail, Peter.Burkhard@uconn.edu. B.C.: tel, 39-0521906613;
fax, 39-0521905151; e-mail, barbara.campanini@unipr.it.
‡ These authors contributed equally to the work.
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| University of Basel.
⊥ Current address: Department of Biochemistry, Albert Einstein
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2.1 Abstract 
 
 
Dopa decarboxylase (DDC) is an important enzyme in the catecholamine biosynthesis 
pathways. Catecholamines, e.g., dopamine, serotonin, etc. often are the major 
neuromodulators or neurotransmitters. Hence, DDC plays a key role in regulation of 
neurodegenerative diseases like Parkinson’s disease (PD). In order to achieve a 
medicine for PD, a successful inhibitor for DDC, that could reduce the activity of 
DDC in the blood while making it more effective in brain, is required. An effective 
design of an inhibitor requires a detailed structural study of human DDC. It was 
aimed to solve the DDC structure by X-ray crystallography. In order to have enough 
protein the DDC encoding gene has been cloned in the pET21d vector which was 
later termed as pET-DDC-His. However, it required numerous trials and errors until a 
suitable condition for soluble DDC expression was found. Addition of additives like 
PLP, ethanol, a complex of sorbitol and betaine in the growth medium of the bacteria 
did not help bring the protein in the soluble part as it formed inclusion bodies. Several 
soluble protein fusions with DDC, like Thioredoxin and Glutathione-S-transferase 
were also not quite helpful towards achieving soluble expression of DDC. Finally, a 
coexpression of DDC along with bacterial chaperone proteins, e.g., GroEL and GroES 
(after cotransforming both the DDC and Chaperone protein encoding plasmid in the 
same E.coli cell, used for expression) lead to solubilization of recombinant human 
DDC. This enzyme was then purified to homogeneity by successively passing the 
crude bacterial proteins through Ni-chelate-affinity chromatography and Size 
Exclusion Chromatography. The purified protein (>90 % purity) did not produce a 
good yield (4mg/ 8L culture), but this was enough to start the initial crystallization 
trial. Using a scale up to a 50 L culture, quite a good amount of protein was achieved. 
The homogeneity of DDC was further confirmed by using Multi-Angle Light 
Scattering and Blue Native PAGE. The dimeric enzyme preparation was then utilized 
for crystallization using the Hanging Drop Vapor Diffusion method. In a particular 
condition of the crystal screens trigonal bipyramidal crystals formed. However, these 
crystals did not show good diffraction when bombarded with X-ray beams. Later, this 
particular crystallization condition remained irreproducible. 
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2.2 Introduction 
 
2.2.1. The Enzyme DOPA Decarboxylase 
 
 
DOPA decarboxylase (DDC) or so called amino acid decarboxylase (AADC), is the 
enzyme involved in the synthesis of the catecholamine neurotransmitters, dopamine 
and serotonin. Tyrosine hydroxylase, another enzyme in this metabolic pathway, 
catalyzes the hydroxylation of a tyrosine residue to produce L-dihydroxyphenyl 
alanine (L-DOPA), which is eventually decarboxylated by DDC to form dopamine 
(Figure 2.1). Dopamine is particularly abundant in brain and basal ganglia and is the 
precursor of the catechol family of hormones viz. epinephrin and norepinephrin. A 
similar sequence of reactions in nervous system produce 5-OH tryptophan in the 
presence of tryptophan hydroxylase, decarboxylation of which by DDC produces 
serotonin. 
 
DDC is a homodimeric pyridoxal phosphate (PLP) dependent enzyme[4]. Ichinose 
et.al.[5] prepared a cDNA clone after screening the human pherocytochroma cDNA 
library with a oligoneucleotide probe corresponding to the partial amino acid 
sequence purified from a tumor. The cDNA clone encoding 485 amino acids 
possesses a molecular mass of 53.8 kD[6]. The conserved amino acid sequence, Asn-
Phe-Asn-Pro-His-Lys-Trp, in human, drosophila, and pig enzymes, has been found 
to be responsible for a possible pyridoxal phosphate cofactor-binding[7]. The protein 
encoded by hepatoma cells is the same as that encoded by adrenal chromaffin-
derived pheochromocytoma cells. 
 
 
 
 
 
 
Figure2.1: Dopamine synthesis pathway. The role of DOPA decarboxylase in 
catecholamine (neurotransmitter) biosynthetic pathway. The picture was collected 
from web.indstate.edu/ 
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2.2.2. Physiological Importance and Regulation of DDC 
 
 
The primary function of DDC in the midbrain is the neurotransmission through 
monoaminergic neurons by involving itself in the synthesis of neuromodulators. Thus, 
DDC actually plays a major role in voluntary movement regulation[8]. Dopamine,  
physiologically the most important neurotransmitter in the substantia niagra, gets 
projected through the dopaminergic neurons and hence, these nurons are the major 
source of dopamine. However, a significant depletion of dopamine level is associated 
with the gradual loss of the number of dopaminergic nerve cells[9] that in turn causes 
poor stimulation of motor-nerves in this mechanistic cascade. Hence, degenerating 
dopaminegic neurons is the origin of motor-dysfuntion, which is manifested in the 
Parkinson’s Disease syndrome. 
 
 
2.2.3. Clinical Relevance of DDC 
 
2.2.3.1. Parkinson’s Disease and it’s Treatment 
 
 
Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder 
most commonly characterized by tremor, rigidity, postural-instability, slow movement 
(bradykinsia) and in extreme cases loss of physical movement (akinsia). The motor 
malfunction is associated with a lower level of stimulation of motor neurons by the 
dopamine depleted impaired dopaminergic neurons[10]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure2.2: Regulation of the production of dopamine in blood and brain. The 
picture was collected from http://www.epda.eu.com 
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PD symptoms are revealed when the level of dopamine in the basal ganglia of the 
brain is abnormally low. When dopamine synthesis deteriorates, the dopaminergic 
neurons start disappearing. Hence, restoring dopamine level back to normal is one of 
the ways of treating PD. However, dopamine cannot be directly administered in the 
blood as this compound cannot pass the Blood-Brain Barrier (BBB) to reach the 
brain. For this reason, L-DOPA, the precursor of dopamine, which can penetrate the 
BBB, is used for the treatment.  
 
The L-DOPA treatment however, had encountered serious side effects like nausea, 
vomiting, blood pressure changes and collapse[11]. This is because, L-DOPA is also 
a component of other peripheral organs like the liver, kidney etc[12]. An elevated 
level of dopamine disturbs the chemical balances in these organs. Therefore, the use 
of the inhibitors, which selectively compete for dopamine production with the rate-
limiting enzyme DDC in peripheral organs, has been recommended to use 
simultaneously during L-DOPA application[13]. Such an inhibitor-aided system 
would help increase the level of dopamine in the brain. A few competitive inhibitors 
of DDC have been depicted in the Figure 2.3 which structurally resemble L-DOPA, 
e.g., carbiDOPA[14], benserazide[15] etc. Therefore, the recent research effort 
mainly focuses on the reduction of L-DOPA dose and lowering of the side effects.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3.2. Schizophrenia  
 
 
The involvement of dopamine and dopaminergic pathways in the disease onset of 
schizophrenia has been confirmed [16]. A multifold decrease in the dopamine level 
 
Figure 2.3. The chemical structures of DDC substrates and inhibitors. The 
substrate L-DOPA and 5 hydroxy-tryptophan together with the inhibitors 
carbiDOPA and benserazide (in its cleaved form) of DDC (Picture is taken from 
Burkhard et. al 2001). 
Structural Characterization of Human DOPA Decarboxylase 
 
 12 
is observed in the sub-cortical region of brain leading to lesions in these areas [17]. 
This type of partial seizure in the brain is responsible for the psychosis as seen in the 
Schizophrenics. These patients with partial seizures evidenced to have significant 
increase in the DDC activity. Apart from dopamine, presence of a few other 
neurotransmitters/ neuromodulators is also indicative of the diseased condition, e.g., 
2-phenylethylamine (2-PE) [16],[18],[19]. DDC, also known as aromatic L-amino 
acid decarboxylase (AADC), takes part as rate limiting enzyme in the production of 
the trace amines, namely, 2-phenylethylamine (2-PE), p-tyramine, and tryptamine 
which are thought to act as neuromodulators. 
 
All of these above mentioned facts/evidences point out towards the importance of 
DDC being an interesting candidate enzyme for its susceptibility to schizophrenia. 
The data of structure -function of DDC is therefore of high demand in the 
development of therapeutic agents for Schrizophrenia.  
 
 
2.2.3.3. Cancer  
 
 
A number of peripheral cancers, namely, pheochoromocytomas are characterized by 
an extremely high DDC activity[20]. The significance of this strong catecholamine 
expression is not readily understandable. Analysis of the amount of expressed mRNA 
shows that the catecholamine production in pheochromocytomas is primarily 
controlled by the level of gene expression [21]. The large increase in DDC activity in 
cancerous cells can be important for chemotherapy. Hence, DDC is a candidate, 
against which the enzyme activated cytotoxic agents can be directed[22]. 
 
 
2.2.4. DOPA Decarboxylase - A member of PLP 
Dependent Enzyme 
 
2.2.4.1. What is PLP? 
 
Chemically, the compound, PLP, is termed as pyridoxal phosphate. It is a remarkably 
versatile coenzyme, categorized in the class of vitamin-B6. Vitamin-B6 enzymes are 
often involved in decarboxylation, racemization, transamination and many such 
reactions related to the modification of amino acid side chains. Three different 
chemical forms of vitaminB6 are mostly available in vivo. PLP is the predominant 
one, while the others are pyridoxine and pyridoxamine 5’-phosphate (PMP) (Figure 
2.4). 
 
2.2.4.2. PLP is One of Nature’s Most Versatile Catalysts 
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PLP-dependent enzymes (B6 enzymes) catalyze a wider variety of different 
reactions than those containing any other cofactor. The common features of PLP 
catalysis underlying these diverse reactions are[23]: 
 
 1) PLP starts to be attached covalently by a Schiff's base linkage to a lysine residue 
located at the active site, giving what is called the “internal aldimine” form of the 
enzyme.  
 
2) Upon binding an amino acid substrate, a transaldimination reaction releases the 
lysine residue and forms an “external aldimine” (PLP is held in place by only non-
covalent interactions) between the substrate and PLP.  
 
3) Finally, the amino acid substrate is hydrolyzed. 
 
The PLP molecule in the Schiff base conformation provides an alternating double 
bond system that helps labializing free electrons and thus stabilizing it[24]. At this 
point, the conjugated orbital system in PLP effectively acts as a temporary electron 
storage site (‘electron sink’), allowing several possible reactions to take place (Figure 
2.5). The strong electron withdrawing system thus helps weaken the sigma bond of 
the α-carbon of the attached amino acid. This way, this particular carbon atom 
becomes an active reaction center on which elimination, substitution etc. processes 
can happen further. The geometry of PLP with respect to the enzyme, is in such a 
way established that an energy minimization is achieved by a sigma-pi 
interaction[25]. 
 
This common mechanism of initial internal and external aldimine complex formation 
guides the further specific reaction path depending on the ionic environment 
provided by the enzyme part, geometry of the intermediate, and/or presence of a 
metal ion[26]. Hence, the ring stabilization of PLP is the key to the versatility in 
action of this cofactor.   
 
Despite the low sequence identity, the structural features of the different proteins are 
conserved amongst the common ancestors (Lesk and chothia 1980). Depending on 
the independent evolutionary lineages [27] the PLP dependent enzymes also have 
been categorized into five distinct structural groups ([28]). The so-called fold-type I 
is the most common structure, and is seen mostly in the aminotransferase and 
decarboxylase enzymes that catalyse α-,β or γ-eliminations[29]. Majority of the fold-
type II group of enzymes catalyse β-elimination reactions[30]. Fold-type III, is 
characterized by a (β/α)8 barrel structure (prominent in alanine racemase and in a 
few types of amino-acid decarboxylases)[30]. Fold type IV mostly constitute the D-
amino acid superfamily of the enzymes. Finally, the fold-type V group includes 
glycogen phosphorylase family of the PLP dependent enzymes[30]. This type of 
limited structural diversity is mostly attributed to the common basic mode of reaction 
that takes place because of the presence of PLP in the enzymes.  
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2.2.4.3 Ketoenamine and Enolenamine Tautomeric 
Equilibrium 
 
 
The tautomeric equilibria between the two forms of Schiff Base viz. enolimine and 
ketoenamine forms, is responsible for showing up two additional peaks at ~335 nm 
and ~420 nm in all of the PLP dependent enzymes apart from the one at 280 nm 
(Figure 2.6). The peak at ~ 420 nm indicates a protonated Schiff base linkage 
between the aldehyde group of PLP to the ε-NH2 group of the representative Lys 
residue from the enzyme (e.g. Lys-303 in the case of pig DDC) indicative of the 
 
Figure2.5: Formation of Electron sink in PLP. The schematic of stabilization 
of PLP dependent enzymes by PLP during nucleophilic attack of the substrate. 
Figure2.4: The three forms of vitamin-B6  
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ketoenamine form of the internal Schiff base (ISB) (Figure 2.6, 2 and 3). The 
absorbance at around 330 nm is due to the enolimine form (Figure 2.6, 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formation of the external Schiff base (ESB) slightly distorts the conenzyme plane, 
i.e., a Met adduct of the enzyme OASS causes 13° tilt of the PLP plane compared to 
that in ISB[31]. This change in geometry is also reflected in the change of λmax  
ketoenamine and enolimine form, depending on the environment provided by the 
enzyme.  
 
 
2.2.5. Structure of Pig-kidney DDC – A Clue to the 
Structure of Human DDC? 
 
2.2.5.1. Structure of pig-kidney DDC 
 
 
Burkhard et al. (2001) [3]describe the three-dimensional X-ray crystal structure of 
the pig-kidney DDC in the ligand-free form and in complex with the anti-Parkinson 
drug carbiDOPA. DDC possesses an α2-dimeric structure - a typical fold of the α-
family of PLP-dependent enzymes. Each of the two monomers in a molecule is 
composed of three distinct domains viz. a large domain, a small domain and an N-
terminal domain (Figure 2.7). One PLP per subunit is bound deep inside the large 
domain. Eight alpha helices encompassing central seven-stranded beta sheet in the α-
β fold make up the large domain. The small domain consists of a four-stranded 
antiparallel beta sheet with three helices residing opposite to the large domain. The 
N-terminal domain forms a cap like structure that flaps over the top of the other 
subunit. This domain consists of two parallel helices joined to an extended strand.  
The first helix of one subunit aligns antiparallel to the equivalent helix of the other 
subunit. Residues 75-77 (N-terminal domain) and residues 433-435 (small domain) 
form a short two-stranded β-sheet.  
 
Figure2.6: Tautomeric and resonance forms of the internal aldimine. 
1) Enolimine structure; 2 and 3) ketoenamine resonance forms. 
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2.2.5.2. Active Site 
 
 
The active site of pig-kidney DDC, as explained by Burkhard et al.[3], constitutes 
mainly the residues from a single monomer even though, it is located near the 
interface of two monomers. In absence of the substrate or ligand, Lys-303 forms a 
Schiff base linkage with the aldehyde group of the PLP molecule. In the ligand free 
form, the carboxyate group of the Asp-271, situated in close proximity to the PLP, 
forms a salt-bridge with the protonated pyridine nitrogen, thus producing a strong 
electron sink stabilizing the carbanionic intermediate and facilitating the 
decarboxylation reaction. The phosphate group of the cofactor is further connected to 
the protein through an extended hydrogen bond network with the residues like Gly 
and Thr from a helix of the large domain. The residual positive charge of this end of 
the helix dipole neutralizes the negative charge of the phosphate moiety. In an 
experiment  previously carried out by Dominici et al [32], an Ala residue replaced 
the Cys-111 or the formation of a disulfide bridge abolishes enzyme activity[3]. This 
is because the sulfhydryl group of Cys 100’ is only 4.1 A apart from that of Cys-111. 
A mobile loop similar to the ‘movable domain’ of β-family enzyme (as discussed in 
the case of OASSA and B in chapter1) was found to be missing in the recombiant 
DDC crystal structure. Seemingly, these 11 residues (328-339) are important for 
catalysis and probably occlude in the active site cleft during the catalytic reaction. 
 
 
 
 
 
Figure2.7: Stereo view ribbon diagram of the polypeptide backbone of DDC. 
The view is directly down the two-fold symmetry axis. One monomer is completely 
red, whereas the other is green (N-terminal domain), cyan (large domain) and blue 
(small domain). The cofactors (PLP) and the inhibitors (carbiDOPA) are shown in 
ball-and-stick representation in yellow. The N-terminal domain of one monomer 
packs on top of the other monomer, resulting in an extended dimer interface. This 
picture was taken from Burkhard. et. al. (2001)[3] 
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2.2.5.3. Inhibitor Binding Mechanism 
 
 
The form of DDC inhibitor carbiDOPA bound mimicks external aldimine structure 
of the enzyme-substrate complex. CarbiDOPA, which structurally resembles the 
substrate L-DOPA (Figure 2.3, Page 28), binds PLP by forming a hydrazone linkage 
through its hydrazine moiety. The catechol ring of carbiDOPA is implanted deep 
inside the active site cavity. Thr-82 of the enzyme, located near the phosphate group 
of PLP, is bound to the 4’-catechol hydroxyl group of the inhibitor (Figure 2.8). His-
192, a highly conserved residue in almost all the α-family PLP enzymes, is placed in 
the front of the active site stacking its imidazole ring plane in parallel over the 
pyridine ring (Figure 2.8). The imidazole ring of His-192 possibly could play an 
important role in catalytic activity, because H192A mutants lose catalytic activity 
completely. Burkhard et al (2001)[3] hypothesize that His-192 catalytically activates 
the side chain of Tyr-332. In the active site Lys-303 displaces the amino group of the 
product through a nucleophilic attack on the imine bond resulting in releasing of the 
product. The reaction is controlled by the specificity of PLP-dependent enzymes, in 
which the external aldimine intermediate orients itself perpendicularly to the 
coenzyme π-bonding system (Figure 2.8). Therefore, the reaction is optimized, 
because the s-p orbital overlap in the transition state is maximized. Upon close 
examination of the complex, the carboxylate moiety of the inhibitor is oriented with 
the Cα-CO2- bond approximately orthogonal to the plane of the coenzyme ring. This 
particular orientation is advantageous to achieve stereoelectric effects directing the 
specificity of the reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure2.8: A stereo diagram of the active site of inhibitor (carbiDOPA) 
bound DDC. The covalent linkage of carbiDOPA with Thr82 and the PLP N 
is shown in this picture. (This picture is taken from Burkhard et al, 2001). 
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2.2.5.4. Sequence Homology of Pig-kidney DDC and 
Human DDC 
 
 
A sequence alignment result shows 87% sequence homology between pig-kidney and 
human DDC enzymes (Figure 2.9). The active site residues important for catalysis 
viz. Lys-303, His-302, His-192, Thr-82, Asp-271 (Figure 2.9.) are unchanged in both 
the homologues. There is a minor change with the similar type of amino acid 
(replacement of Lys-431 with Arg-431) at the C-terminus of the sequence that is near 
the domain that is responsible for making a two stranded β-sheet with the N-terminus 
part of the sequence. The remarkable change in the DDC is only limited to a region of 
two successive amino acids of human DDC viz. Asn-134 and Glu-135 which replace 
Ala-134 and Gly-135 in the pig-kidney enzyme. Another region, which has an 
interesting difference, is the residue just prior to the conserved Tyr-332. While in the 
pig-kidney DDC there is a hydrophobic residue adjacent to this amino acid, in human 
DDC the residue is replaced by a hydrophilic Thr-331 residue (Figure 2.9). All these 
changes in the sequence could help in modeling the human DDC structure and 
possibly could throw light on the approximate interaction that possibly could take 
place. But, the best way to understand the effect of these changes in residues or to 
explain the differences in solution behavior of these two enzymes, the structure of 
human DDC needs to be solved. 
 
 
2.2.5.5. Structure Based Drug Design 
 
 
Structure based drug designing is an improved technique over the traditional drug 
library screening. Such a designing process relies on the availability of the active 
site/regulatory domain cleft conformation of the disease related protein/enzyme 
target so that a small organic molecule, whose binding specificity to the very cleft 
resembles that of the natural substrate, could be synthesized in-vitro. The binding site 
structure, which eventually works as a mould to generate a precise ‘lead’ in drug 
discovery considering the three dimenstional steric, hydrophobic and hydrogen-bond 
interactions, could be best gathered by the X-ray crystallographic technique.  
 
As described before, the high demand for effective PD treatment necessitates 
discovery of a potent inhibitor for DOPA decarboxylase in order to stop this enzyme 
action in blood, converting L-DOPA to dopamine. Despite the fact, the pig kidney 
DDC structure is now known, many other mechanistic questions related to inhibitor 
and human DDC interaction remains. The crystal structure of human DDC would 
assist in providing a stronger platform in developing more potent DDC inhibitors 
than the ones that have been used recently. The new drugs with the improved 
pharmacological character might allow for reduction of dosage of L-DOPA and 
hence could reduce very undesirable side effects. 
 
 
Structural Characterization of Human DOPA Decarboxylase 
 
 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 Scope of The Work 
 
 
The scope of this thesis work includes purification, characterization and 
determination of the structure of Human DDC. X-ray crystallography was intended 
to be used in order to solve the structure of DDC.  
 
 
Figure 2.9:  Sequence alignment of human- DDC and pig kidney- DDC 
showing 87% homology. Green oval marked area in the sequence are those which 
are stabilized by making an inter-domain β-sheet formation. The green arrowed 
amino acids represent the most conserved and catalytically active amino acids. 
Alignment was done using ClustalW, PBIL. 
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Chapter 3 
 
 
 
De-novo designed nanoparticles - an efficient 
pharmacological tool
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3.1. Abstract 
 
 
The peptide nanoparticle, designed and produced in our lab, could possibly be a very 
valuable tool in biomedical applications, e.g., in designing vaccines, delivering drugs, 
bioimaging, serodiagnosis, etc. The design of the peptide nanoparticles is based on the 
application of the symmetry elements of virus icosahedral capsid on a specially 
designed building block peptide. The designed peptide building block contains two 
oligomerization motifs, i.e., a trimeric coiled coil and a pentameric coiled coil joined 
by a linker region. Sixty such peptide units, upon self-assembly, would produce 
peptide nanoparticle mimicking a small icosahedral virus particle. The peptide chains 
in the building block provide flexibility in the design so that an additional peptide 
could be attached to it at the C-terminus in order to functionalize the peptide 
nanoparticle for various biomedical applications.  
 
First of all, the functional peptide at the C-terminus could be an epitope for the 
antibody of a life threatening disease like HIV. These peptide nanoparticles can then 
function as the potent vaccine candidate for that particular disease. In this thesis work, 
I have attached the two epitopes against the two broadly neutralizing classes of 
antibody for HIV infection, 2F5 and 4E10, to the peptide nanoparticle.  
 
Secondly, another sequence of peptide, which proved to have the capacity of seeding 
gold on its surface, was attached to the building block peptide unit. The nanoparticle, 
functionalized with such a peptide, can decorate a gold layer surrounding it. Gold 
coating on the peptide nanoparticle scaffold can provide a nanostructure, called 
‘nanoshells’, which could be very important in the field of therapeutics because of its 
ability in easy detection and quick treatment of cancer cells. 
 
Lastly, I added three peptides; those are recognized in the culture filtrates of 
M.tuberculosis isolated from TB patients, separately, to the basic peptide construct to 
form three different nanoparticles. Also, I tried to make a single nanoparticle that 
displays all the three peptides on its surface. Such a nanoparticle could be a very 
useful tool in the serodiagnosis or the antibody-based rapid detection of the deadly 
disease- Tuberculosis.  
 
The nanoparticle formation in each of the above-mentioned cases was more or less 
successful. One of the constructs could successfully even produce gold shells on the 
peptide nanoparticle.  
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3.1 Introduction 
 
3.1.1.  Nanoparticles 
 
 
“There is no accepted international definition of a nanoparticle, but one given in the 
new PAS71 document developed in the UK is: "A particle having one or more 
dimensions of the order of 100 nm or less". 
There is a note associated with this definition: "Novel properties that differentiate 
nanoparticles from the bulk material typically develop at a critical length scale of 
under 100 nm". 
The "novel properties" mentioned are entirely dependent on the fact that at the nano-
scale, the physics of nanoparticles mean that their properties are different from the 
properties of the bulk material. 
This makes the size of particles or the scale of its features the most important 
attribute of nanoparticles.” (An extract from http://www.malvern.co.uk/) 
 
3.1.2.  Peptide Nanoparticles 
 
 
The novel type of nanoparticles, de-novo designed and being produced in our lab, 
mimicking the symmetry of polyhedral virus capsids (Figure 3.1), are meaningfully 
termed as Peptide Nanoparticles (specific design strategy will be discussed in a later 
section). In principle, formation of such a nanoparticle takes place in-vivo by the 
self-assembly of a single chain polypeptide comprised of two oligomerization motifs 
i.e. a pentameric and a trimeric coiled coils connected through a linker. Such a 
designed system allows formation of nanoparticles of 16 nm in diameter and 473 kD 
molecular mass [3]. Properly functionalized peptide nanoparticles could be suitable 
for drug-delivery, diagnosis and treatment of human diseases [4]. This could again be 
used as an efficient vaccination tool simply by attaching an antigen to the surface of 
the nanoparticles, leading to so-called “Repititive Antigen Display”[5].  
 
3.1.3.  Peptide Nanoparticles and Drug Delivery 
 
 
A successful drug delivery vehicle should have the following characteristics: ability to 
accomplish controlled release of drugs, biocompatibility, bioavailability, limited 
toxicity and capacity of better targeting the specific tissues [6]. The drug delivery 
vehicles that are presently being used possess limitations due to toxicity and side 
effects, poor stability and suboptimal bioavailability due to short half-life in the blood 
stream [7]. The side effects of these drugs stem from poor targeting and hence, a high 
dose of administration. Therefore, a good drug delivery vehicle should 
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accomplish an effective cell targeting. Also, it has been observed that the particles 
with sizes less than 10 nm are rapidly excreted from the system. Hence a particle size 
of 10-100 nm is optimum for designing the new generation drug delivery system[8].  
 
Nanoparticle-based drug delivery vehicles using biopolymers are thought to be the 
best. The sizes of the nanoparticles can be made so that they fall in the optimum size 
zone for an effective drug administration system. The ease of manipulation of such 
particles for controlled pharmacological needs is one of the valuable properties that 
could be utilized. Also, being biopolymer based, these systems are biodegradable. 
 
The designed peptide nanoparticles in our lab would be of a diameter of ~20 nm.  
Owing to their biodegradability and cage like structure having a cavity of 6-10 nm 
diameter at the center (Figure3.6), they could be a useful mean for drug transport in 
the blood stream. The morphology, size, shape and targeting eficiency can be easily 
modified at the molecular level [9]. They can be used to deliver both small-molecule 
drugs and various classes of biomacromolecules, such as peptides, some inorganic 
compounds like gold, and quantum dots for use as a biosensor (to be discussed in 
detail later).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure3.1: Structure and geometry of icosahedral viral capsid. 
A) Icosahedron elements with its symmetry  
B) X-ray crystal structure (1DNV) of the insect parvovirus (Galleria 
mellonella denso-virus) with icosahedral symmetry. The protein chains 
are colored from red (N-terminus) to blue (C-terminus) and one single 
protein molecule is highlighted. The view is down the five-fold 
symmetry axis.  
 
2-fold axis of 
symmetry 
5-fold axis of 
symmetry 
3-fold axis of 
symmetry 
(A) (B) 
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3.2.4. Peptide Nanoparticles and Vaccine Design 
 
 
Peptide nanoparticles could also be designed as an effective tool for vaccination. 
Vaccination with peptide nanoparticles utilizes the concept of Repetitive Antigen 
Display (RAD). Nanoparticles, with an immunogenic peptide attached to it, can 
exhibit several copies of the same antigen on its surface, thus, elevating the levels of 
antigenic response a few fold more than a single copy of the antigen. Hence, the 
epitopes for deadly pathogens e.g. HIV (Human Immuno-deficiency Virus), SARS-
Virus (Severe Acute Respiratory Syndrome Virus), pseudomona, can be easily 
engineered on the surface of such peptide nanoparticles with a view to elicit a high 
content of neutralizing antibody in the blood sera and generate a variety of different 
vaccines. One of the major advantages of such a vaccine candidate is, that it does not 
require the use of a live attenuated virus, although it mimicks the geometry and 
property of the RAD of a virus or virus-like particle (VLP). Therefore, the ease and 
flexibility of design excluding the use of living virus particles makes it an attractive 
strategy in the field of vaccine design. 
 
 
3.2.4.1.  Vaccine for HIV 
 
 
According to the census report of 2006 39.5 million people are suffering from HIV 
infection among which 4.3 million are newly affected in the very year worldwide 
(http://data.unaids.org/pub/EpiReport/2006). Therefore, a vaccine to prevent HIV-1 
infection or to reduce disease progression in infected individuals is an urgent public 
health requirement [10]. However, generation of an HIV vaccine is still a goal yet to 
achieve.  
 
The understanding of the progression of the disease becomes easier when 
considering the structure of the virus gp41 protein of the HIV-1 envelope 
glycoprotein, which represents the core of fusion-active gp41[11, 12]. A probable 
mechanism of formation of a host-virus fusion complex is described in the Figure 
3.2. Generation of an antibody against this fusion complex could inhibit the infection 
of HIV and hence this complex is a potent target for vaccine design. Visualization of 
the structure of gp41 could help identify a mean that resists the interactions between 
gp120 and the CD4+ coreceptor of the infecting cells[11] 
 
 
3.2.4.2.   What are gp41, gp120 and gp 160? 
 
The HIV membrane has about 9-10 spikes of the glycoprotein (gp) called gp160 
which are embedded and are generally involved in binding and membrane fusion of 
the virus particles to the host cell [13] (Figure 3.3). The two proteins gp41 and gp120 
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are two proteolytic products of gp160. Gp41 is membrane bound and gp120 resides 
in the membrane exposed part[14]. Gp120 is responsible for binding of the virus to 
its receptors and coreceptors. gp41 is comprised of an ectodomain, a transmembrane 
domain and a cytoplasmic domain. The extracellular domain mediates the fusion 
process (Figure 3.2). An N-terminal and a C-terminal heptad repeat motif (suggestive 
of coiled coil structure) of the ectodomain forms a fusogenic active 6-helix bundle 
structure (Figure 3.2) to facilitate the virus genome transfer to the host cell [15].  
 
 
3.2.4.3.  Vaccination Strategy: 
 
 
The challenges to produce an HIV vaccine are as mentioned below: 
 
a)  CD4+ cells are the most important cells for the immune response to take 
place in the human system. These cells help form the secretory antibodies after 
interaction with the fragments of antigen bound B-cell. Hence, CD4+ cells 
thought to be giving the first line of defense in the human body against any 
foreign immunogen. HIV attacks on these very CD4+ cells by drastically 
diminishing immunoresponsiveness of the host cells 
 
b) After infection, HIV undergoes mutations and recombinations inside the host 
cell to evolve into a new type of virus strain. So, to generate an antibody that 
will be effective for all the new clades are very difficult as it gives rise to 
enormous antigenic variation. 
 
c) Most of the envelope proteins are heavily glycosylated making the antigenic 
epitopes inaccessible for antibody binding.  
 
d) Lack of any animal model to test the efficacy of the designed vaccine. 
 
 
Hence, the remedies to the above obstacles can be generated by the following means. 
 
a) An antibody response should be made so that the fusion of the virus with the 
CD4+ cells is restrained. Hence, to design the vaccine the antigenic region 
should be chosen in such a way that it is located in the gp41/ gp120 envelope 
trimer that is responsible for the virus attachment.  
 
b) The successful vaccine must be effective against a large number of different 
HIV variants (broad spectrum). It is a prerequisite to develop vaccines against 
a conserved region of the HIV epitopes, which are common to all the HIVs or, 
at-least, in most of the HIV subtypes.  
 
  A Repititive Antigen Display (RAD) system can resolve the problems of low titer 
antibody response. It has been seen that the highly ordered display of antigens, which 
is termed as RAD, on the surface of a virus or bacteria is effective in causing several 
fold higher immunogenic response.  
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d) An effective vaccine is likely to include components able to induce humoral 
and cellular immune response[16].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this thesis work, the HIV vaccine design was performed following the line of 
action as stated above.  
 
 
a) Choice of the epitope: Elicitation of broadly neutralizing antibodies (i.e. 
antibodies those reduce or abolish the biological activity of the soluble 
antigen) against HIV-1 by immunization is a major challenge in developing a 
vaccine against the AIDS [17]. The immunogens that mimic the native 
structure of the gp41 ectodomain glycoprotein are found to form the most 
potent neutralizing antibodies. Only a few region of the envelope glycoprotein 
are actually accessible by the antibodies. A few human monoclonal antibodies, 
having the capacity to neutralize a broad range of primary isolates of HIV-1, 
have been isolated [18]. There are two monoclonal antibodies against the two 
vulnerable stretches of the transmembrane glycoprotein gp41 near the 
membrane proximal external region (MPER), namely, 2F5 and 4E10 [19, 20] 
(Figure 3.3). The MPER of gp41 is highly conserved, and several studies have 
implicated it as an essential part of the cell fusion machinery [21, 22]. For 
vaccine development, linear neutralizing epitopes have a potential advantage 
over more complex ones. Owing to the linear nature of the neutralizing 
epitopes it bears and to its high amino acid conservation, the MPER of gp41 is 
an attractive target for HIV-1 vaccine development. They have been found to 
be effective at a high concentration in protecting macaques from simian HIV 
challenge [23, 24]. 2F5 has been found to have a broad and potent neutralizing 
activity against primary HIV-1 isolates[25, 26]. A six-amino acid long peptide 
Figure 3.2. Working model of HIV-1 membrane fusion and its inhibition. Before 
exposure to cellular receptors, Env exists in a native state ("Native"). After 
interaction with CD4 and the coreceptor, a conformational change allows gp41, to 
form a transient prehairpin intermediate ("Prehairpin")[2]. (Figure is taken from the 
manuscript PNAS with a prior permission from Dr. Peter Kim). 
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sequence (ELDKWA) [27, 28] located near the C-terminus of the gp41 
functions as the epitope and is well accessible by the antibody[29] [30]. 
Stiegler et. al.[31] reported that, 4E10 binds to a linear, highly conserved 
region of MPER (671-683) C-terminus to 2F5 epitope. Recent 
crystallographic structure determination has revealed the 4E10 epitope adopts 
a helical structure causing an effective structural constraint towards antibody 
production. The core peptide sequence of this epitope contains WF(D/N)IT 
[32] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) RAD:  It is also desirable to elicit the antibody response in high titer in order 
to make an effective HIV-1 vaccine [17]. The immunogenic peptide (2F5-
4E10) was attached to the peptide nanoparticle building block unit. 60 such 
monomeric units, upon self-assembly produce peptide nanoparticle with the 
HIV epitopes protruding out of the surface. Therefore, a single peptide 
nanoparticle unit is capable of displaying 60 antigenic peptides on its surface. 
This phenomenon of exhibiting multiple copies of the same epitope satisfies 
the concept of RAD. 
 
c) Generation of humoral immunity: The antigenic 2F5-4E10 coupled epitope 
coupled to the peptide nanoparticle would be capable of eliciting strong 
humoral immune response. 
These two broadly neutralizing antibodies (MAbs) 2F5 and 4E10, established by 
Katinger et. al. recognize linear epitopes whose core representative sequences  
ELDKWA (2F5) and NWF(d/N)IT (4E10), are located just before the TM (Trans 
Membrane) region (Figure 3.3). The whole stretch containing the 2F5 and 4E10 
epitope has been selected to be the antigenic peptide to be exhibited on the peptide 
nanoparticle. 
 
 
Figure3.3: Membrane proximal region of gp41 ectodomain in 
the HIV-1 virus membrane. The inset Figure clearly shows the 
location of the 2F5 and 4E10 antibodies binding sites. (Picture 
is taken form Nabel et al.[1]). 
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3.2.4.4.  HIV-1 Vaccine Design 
 
 
In this thesis, I report design of a nanoparticle with a peptide containing two of the 
HIV-1 epitopes, such that during the nanoparticle formation, the antigens for HIV-1 
(a stretch of the gp41 containing the epitopes for 2F5 and 4E10) are displayed on the 
surface. This C-terminus HIV-1 epitope fusion with the nanoparticles could be used to 
achieve high titer antibodies by immunizing animals against HIV.  
 
 
3.2.5.  Nanoparticles and Biosensing 
 
3.2.5.1. What is Biosensing? 
 
 
“A biosensor is a device for the detection of an analyte that combines a biological 
component with a physicochemical detector component” [33]. A biosensor is 
composed of a sensing element, a sensitive biological element and a transducer. The 
sensing element identifies a particular species of interest through a specific reaction, 
absorption, or other physical or chemical process. The transducer maintains a 
connection between the other two elements and converts the results of this 
recognition into an electrical or optical signal that can be measured easily.  
 
 
3.2.5.2. Peptide Nanoparticles in Biosensing 
 
The thermo-optical properties of gold nanoparticles conjugated with the peptide 
nanoparticles expected to be a unique invention in the field of biomedicine. The 
coherent oscillation of the free electrons or the “surface plasmons” on the surface of 
the gold nanoparticles, is responsible for their unique optical absorption profile [34]. 
Surface plasmon resonance of the gold nanoparticles is sensitive to the change in the 
local environment/surface properties and results in a shift in the characteristic 
absorption spectrum. Hence, the optical properties of these particles are the function 
of geometry, shape and size and dielectric properties of the surrounding 
medium[35],[36]. Therefore, by controlling the dimensions and geometry, it is 
possible to manipulate the absorption and scattering wavelengths generated from 
gold nanoparticles. The above mentioned properties of gold nanoparticles had drawn 
attention in a wide variety of biomedical applications. 
 
Gold and peptide nanoparticle composite can be made either by incorporating the 
gold nanoparticles in the core of the peptide nanoparticle or by decorating the 
peptide nanoparticle with the gold shell. These nanocomposites can be potentially 
used beacuse of their biocompatibility and biodebradability of the peptide unit. By 
adjusting the relative sizes and geometries of the core and the shell the optical 
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resonance of gold nanoshell can be manipulated in a very wide  range; visible region 
to the infrared region [37] [38].  
 
 
3.2.5.2 .1.  Cancer  Therapy  
 
 
An early detection of the metastases is the key challenge in the treatment of cancer. 
Until recently, there were no noninvasive method of detection and destruction of the 
cancer cells. Selective targeting of the cancer cell, leaving the healthy cells intact, is 
the major goal of modern cancer therapeutics[39]. Near IR radiation, coupled with 
metallic nanoparticles, confers an effective noninvasive technique in cancer detection 
and therapy. Such an IR radiation is chosen because of its nonionizability and tissue- 
penetrating capacity[40]. Flurophor or MRI contrast agent labelled metallic 
nanoparticles, after targeting to the diseased cells, when irradiated with near IR helps 
in visualizing metastases. The heat generated due to absorbtion of the incident 
radiation induces death of the affected cells. This is a very sophisticated 
improvement in the cancer therapeutics over the conventional surgical treatment in 
terms of precision and noninvasiveness. Moreover, in most cases, surgical therapy is 
unsuitable for early metastases and often affects the neighboring healthy tissues 
during the tratment process.  
 
 
3.2.5.3. Gold Attached Peptide-Nanoparticle and 
Biosensing 
 
 
Gold particles either can be layered on the nanoparticle surface making a gold 
nanoshell or incorporated inside the cavity of the peptide nanoparticle. The cancer 
cells generally have  leaky membranes. Peptide nanoparticles bearing gold decorated 
in the surface diffuses well into the porous membrane of the cancer cells. The 
accumulated nanoparticles in the diseased cell upon illumination with near IR 
radiation would produce heat, which could help in visualization and photothermal 
destruction of the cells[41]. The gold nanoshells on the peptide nanoparticle scaffold 
are expected to have a broader range of wavelength absorption and scattering 
intensity, depending on the geometry of the composite structure and the thickness of 
gold making up the shell. The tunability of such particles make it a significant tool in 
the field of therapeutics. The tunability of these particles is exhibited by controlled 
variation of the core (peptide nanoparticles) and shell (gold nanoparticles) ratio 
(Figure 3.4). 
 
In this thesis work for making gold and peptide nanoparticle composites, a peptide 
(e.g. A3 peptide[42]) that helps in seeding gold on its surface (constructs P3a_BB3) 
was attached to the peptide nanoparticle. 
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3.2.5.3 .1.  Object ives 
 
 
The objective of this project is to generate a novel nanocomposite using peptide 
nanoparticle and gold nanoparticle, having unique spectroscopic properties. The 
peptide nanoparticle is used as a scaffolding device to conjugate surface modified 
gold nanoparticles.  
 
 
3.2.5.4.  Development of Peptide Nanoparticle Based 
Serodiagnosis Tools for M.tuberculosis  
 
 
Tuberculosis or TB is Mycobacterium tuberculosis mediated airborne infectious 
disease, still remains as one of the deadliest in the world. Although, between the 
years 1985 and 1992 a considerable decrease in the number of cases in USA was 
observed, after this period, a threatening number of cases have been reported. This 
increment can be attributed to several factors, i.e., 
 
A) Appearance of Multi Drug Resistant (MDR) strains of Mycobacterium 
 
B) Occurrence of Extensive Drug Resistant strain of Mycobacterium Tuberculosis, 
the so-called (XDR) 
 
C) Incidences of HIV 
 
Depending on the diseased states, TB could be of two types: Active and Dormant/ 
Latent. According to an estimate by the World Health Organization (WHO) in the 
year 2005, 8.8 million people worldwide reported to be infected with active 
tuberculosis and among them, nearly 1.6 million died[43]. Among these, over 90 % 
of the population constitute the cases from developing countries[44]. Active 
tuberculosis is the more fatal type of the two and develops the signs and symptoms 
of the disease, while, in the cases of latent tuberculosis the antibodies against the 
Figure 3.4.  Depiction of the growing gold nanoparticles on the surface of the peptide 
nanoparticle. The diameter of the gold nanoparticles is indicated above. At a diameter of 
about 15 nm the gold nanoparticles start to aggregate and to form a gold shell around the 
peptide nanoparticle. The shell is already closed at 18 nm. The diameter of the whole 
complex of the rightmost particle is about 50 nm. 
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bacteria form a layer surrounding the infection nuclei and resist the disease 
progression. However, in suppressed immune condition, i.e., HIV infected system or 
in condition where immunosuppressant drugs had been used, likelihood of 
developing tuberculosis is higher.  
 
 
3.2.5.4 .1.  Clinical manifestat ion  of  Tuberculosis 
 
 
Several factors determine the clinical manifestation of TB. The cumulative effect of 
all the factors results in remarkable variability in the disease progression. 75-85 % of 
the TB cases are found to be predominantly pulmonary[45]. Extra-pulmonary 
tuberculosis generally involves heart, kidney, lymph node, central nervous system, 
and genitourinary tract, etc. Extrapulmonary TB is more prevalent in children than 
adults. However, this proportion of pulmonary and extrapulmonary tuberculosis is 
quite different in the immuno-compromised system, e.g., in the HIV infected 
body[46]. Fever is the most common symptom of the disease, though there are many 
a cases where, at no point in the diseased stage, there was any fever. Loss of appetite, 
night sweatness, weight loss, weakness and malaises are other common signs of 
Tuberculosis. However, these symptoms are diagnostically difficult to pinpoint, as 
they are often confused with other diseases, if any, are coexisting. Extrapulmonary 
tuberculosis is the less frequent of the two types and less knowledge is available to 
the clinicians about it. Also, in these cases there is only limited access to the diseased 
organs, which again causes the trouble in detection of the disease. 
 
 
3.2.5.4 .2.  Diagnosis  of  Tuberculosis  
 
 
Generally one or more of the procedures as mentioned below are used in the 
diagnosis and determination of the efficacy of a given treatment of tuberculosis.  
 
Diagnostic microbiology: Sputum test for Acid Fast Bacilli (AFB): Because 
mycobacterial infection can occur at almost any site of the body, a variety of samples 
from various sites could be submitted for the examination of the presence of the 
bacteria. The most common of the specimens is the sputum (mostly for pulmonary 
pathology), while the others include gastric filtrate, urine, cerebrospinal fluid 
etc.[47]. Following collection, the specimens are transported to the designated 
laboratories ASAP. The detection of the mycobacterium is routinely done by making 
a smear of the specimen and incubating it with an Acid Fast Dye, e.g., auramine (TB 
Fluorescent Stain Kit M; Difco Laboratories, Detroit, MI). This type of staining 
procedure is dependent on the dye-retaining capacity of the mycobacterium. The 
detection of the AFB in the stain is the first diagnostic evidence of the presence of 
mycobacteria[47]. However, a negative AFB test does not preclude the possibility of 
TB as optimum numbers of bacilli should be in the specimen for the successful 
detection ~ 5000-10000[48]. If the number is below that, it gives a false negative 
sputum test. 
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Tuberculin skin test: A positive Tuberculin Skin test is the indication of the latent 
tuberculosis[47]. This particular test is based on the fact that a few culture filtrates 
“purified protein derivatives”(PPD) or “Tuberculins” show delayed type of 
hypersensitivity in the patients who have been exposed to Mycobacterium. 
Tuberculin extract is injected below the skin in the forearm. A positive response is 
seen depending on the presence of active or latent TB in the patient after 24 -72 hr., 
showing a red swelling in the injected zone. Basically, this result is an example of 
the T-cell mediated response, where T-cells sensitized by prior infection accumulate 
in the injected tuberculin spot and secret lymphokines[49]. However, a tuberculin 
test cannot predict how long one has been exposed to the infection. 
 
Chest X-ray: In the chest X-ray, there is a typical impression formed in the plate 
characteristics of tuberculosis infection. The appearance of several white areas in the 
dark background signifies such an infection[50]. However, sometimes the pulmonary 
lesions are not associated with positive radiograph images[51].  
 
  
3.2.5.4 .3.  Diff icult ies in  Diagnosis 
 
 
The difficulties in diagnosis of tuberculosis stems from the fact that the disease is 
very slow progressing. Until it reaches a reasonably advanced stage, the symptoms of 
the disease are not so prominent.  
 
The limitations of the diagnosis tools that are recently being used are multifold and 
are explained as follows.  
 
a) Mostly, a negative sputum test outcome results in several visits of the patients 
and requires multiple samples and eventually the diagnosis is delayed[52]. The 
delay in identifying TB is responsible for 20 % of the TB transmission [53].  
 
b)  Microscopic examination is not sensitive, as it is dependent on the skill and 
mental condition of the micrscopist[44]. 
 
c) Symptoms of Extrapulmonary tuberculosis is nonspecific. 
 
d) Granuloma culture and histological examination are not commonly available in 
the developing countries where the majority of the cases are being reported[54]. 
 
e) Due to the complexity and expensiveness in the invasive techniques it could not 
be practiced in the developing countries[52].  
 
f) Present diagnosis methods are time consuming because of the slow growth rate 
of M.tuberculosis. This leads to high mortality rate. 
 
Because of the above mentioned limitations, especially in the resourcefully 
challenged countries like India, Taiwan, Tanzania, it could be useful if any rapid and 
sensitive tuberculosis detection method could be employed. One such technique 
could be immunobased serodiagnostic system.   
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3.2.5.4 .4.  Serological  Diagnostic System  
 
 
The serological diagnostics assay relies on detection of antibodies in the serum of the 
respective patients. The previously developed serodiagnosis helps detecting, to some 
extent the pulmonary TB. However, to date, to our knowledge, there is no such 
detection system for extrapulmonary cases of the disease[54]. Also, a rapid diagnosis 
tool for paucibacillary TB is required immediately. The immune based system for the 
detection of tuberculosis has been unsuccessful for years. However, recently, the 
discovery of a few reactive antigens in the culture filtrate of M.tuberculosis that are 
recognized by the antibodies in the multibacillary and paucibacillary HIV+TB and 
HIV-TB patients, sounds promising in the diagnosis of pulmonary and 
extrapulmonary TB[55]. The two of these antigens are reported to be mycobacterium 
Malate synthase (MS) (an 81 kD enzyme) and MPT51 (a 27 kD protein) and these 
antigens are found to have their counteracting antibodies in HIV-TB+ patients 
(pulmonary) who are smear-positive from India[56]. Among the 60 smear positive 
TB patients studied in an experimental set up, 47 (78%) had anti-MS and 41(68%) 
had anti-MPT51 antibodies. Hence, 49 out of 60 patients (82 %) were shown to have 
either one or both of the antibodies as biomarkers in their sera[44]. The laboratory of 
Prof. Suman Laal at NYU, is constantly working on these antigens and already have 
shown experimental results which gives strong support for the effectiveness of these 
antigens as biomarkers in detecting incipient subclinical TB[44].  
 
The advantages of the serodiagnostic tests are as follows: 
 
 
1. They are cheap and easy to perform[54]. 
2. The specimen or the samples do not need to be from the site of infection[54]  
3. Promptness in detection is one of the advantages of this type of technique that 
can be adapted for the so-called “point of care format”[54]. 
4. MS-MPT based serodiagnostic assays can very well serve for the detection of 
pulmonary TB as an adjunct to the sputum test[54].  
5. This system is highly specific and sensitive in the detection of TB in a 
particular TB endemic region[44].  
6. Performances of these particular biomarkers are not hampered due to the 
presence of HIV infection[44].  
 
This MS_MPT based serodiagnostic system is capable of identifying sub-clinical 
TB[44].  
 
Prof. Suman Laal in her laboratory at NYU has performed several tests in order to 
optimize a serodiagnostic tool. By the use of peptide mapping, they have found three 
different antigenic regions of the Malate sythase enzyme, which are mostly 
recognized by the antibodies in the sera of the TB patients at different stages and 
diseased conditions (data has not been published yet). Three regions of the Malate 
synthase enzyme sequence show the most immunogenicity, which correspond to the 
followings, i.e., 192-211, 237-258 and 620-630.  
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3.2.5.4 .5.  Peptide Nanopart ic le in Serodiagnosis of  
Tuberculosis 
 
 
The three peptides corresponding to the immunogenic regions of MS were designed 
to attach to the de-novo designed peptide nanoparticle constructs. Because of the size 
and RAD capacity, these nanoparticles will be able to expose multiple times on its 
surface and would have the ability to aggregate more strongly with the antibodies in 
the sera. Hence, the peptides attached to the nanoparticle would be more rapid and 
sensitive in terms of reaction to take place in the sera of the TB patients. In this 
thesis, I have tried to produce a single peptide nanoparticle on which all the three 
above-mentioned TB-antigenic peptide would be exhibited. Such a system with 
multiple malate synthase antigens displayed on the surface could be the most 
effective in showing the agglutination in the serodiagnostic assay settings. Here is a 
cartoon of what might happen in the blood serum of the TB infected patient when the 
nanoparticle based multiple antigen display system comprising of three antigens are 
exposed to the respective antibodies. The reaction mechanism that could take place 
leading to agglutination has been pictorially depicted in the Figure 3.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: The agglutination of the antibodies in the presence of the antibodies. 
Antigens are the highly immunogenic parts of malate synthase attached on the 
surface of the peptide nanoparticle. 
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3.3. Objective of the Current Research 
 
 
The primary aim of this thesis work is to produce a peptide nanoparticle. These 
nanoparticles were so designed to enable flexibility in addition/deletion/replacement 
of any sequence to the existing one with a view to improve the physical and chemical 
properties of them. One of the two constructs was so manipulated that it would 
produce a higher amount of protein than the other constructs being worked on in the 
lab. A higher yield would lessen the job of repeated protein extraction/purification 
provided the proper storage conditions for the produced nanoparticles are known. 
After successful formation, such peptide nanoparticles would be functionalized for 
various biomedical applications, e.g., designing HIV vaccine, producing 
serodiagnostic tools for Tuberculosis, gold seeding, making a gold nanoshell around 
the peptide scaffold. Along with the new construct the functional nanoparticles from 
the conventional construct (i.e., P3a) would be worked on and compared with the 
new one. Functionalized nanoparticles would be then characterized biophysically 
using CD spectroscopy, DLS, TEM etc. The efficency of vaccination of the HIV 
conjugated nanoparticle would be checked by immunzing the animal model (rat).  
 
 
